PDCD1 and lymphopenia: Several factors might contribute to the blunted efficacy of the anti-PD-1 regimen directly or indirectly, including infiltration of immunosuppressive myeloid cells, sequestration of T cells, release of inhibitory metabolites, and glucocorticoid-induced lymphopenia (34–37).